REG - Genedrive PLC - MOU with Kingdom of Saudi Arabia for MT-RNR1 ID

GenedriveAnnouncement

28/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251028:nRSb0116Fa&default-theme=true

RNS Number : 0116F  Genedrive PLC  28 October 2025

genedrive plc

("genedrive" or the "Company")

 

Memorandum of Understanding with Kingdom of Saudi Arabia Ministry of Health

to introduce the Genedrive® MT-RNR1 ID Kit under Generations Hear programme

 

genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company,
announces that genedrive's exclusive distribution partner in the Kingdom of
Saudi Arabia ("KSA"), iDeal iDea for Medical Equipment Technology has signed a
Memorandum of Understanding ("MOU") with the KSA Ministry of Health ("MOH").
The MOU scope is to pilot the Genedrive® MT-RNR1 ID Kit for potential
national implementation under a national initiative "Generations Hear".

 

The MOU was signed by Hatim Najjar, Founder and CEO of iDeal iDea, Dr Abdullah
Al-Sohimi, General Director of Specialized Centers at Ministry of Health, and
Dr Salem Baharoon, Deputy Minister for Therapeutic Services, Ministry of
Health.

 

 

This initiative aligns with the Saudi Vision 2030, supporting the national
objective of advancing precision medicine, enhancing quality of life, and
transforming healthcare from reactive treatment to proactive prevention, from
disease management to preventive care, and from pain to hope.

 

Dr Gino Miele, CEO of genedrive plc, said: "We are delighted with the signing
of this MOU, which builds further on our commercial traction in Saudi Arabia
and aligns perfectly to the long-term Saudi health goals.  We are grateful to
our valued partners at iDeal iDea for their support and look forward to
progressing through pilot phase with the goal of implementation at national
level."

 

Hatim Najjar, Founder and CEO of iDeal iDea for Medical Equipment Technology,
said: "The Generations Hear initiative embodies Saudi Arabia's true
transformation in the healthcare sector, leveraging genetic innovation to
safeguard the health and lives of future generations. At iDeal iDea for
Medical Equipment Technology, we are proud to provide innovative medical
solutions in line with Saudi Vision 2030 and the Health Transformation
Program, through national partnerships that advance precision medicine and
strengthen preventive healthcare."

 

For further details please contact:

 

 genedrive plc                                     +44 (0)161 989 0245
 Gino Miele: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Broker)      +44 (0)20 7418 8900
 James Steel

 Walbrook PR Ltd (Media & Investor Relations)      +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                   (mailto:genedrive@walbrookpr.com)
 Anna Dunphy                                       +44 (0)7876 741 001

 

About genedrive plc (http://www.genedrive.com (http://www.genedrive.com) )

 

genedrive plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile and simple to use point of need
pharmacogenetic platform for the diagnosis of genetic variants. This helps
clinicians to quickly access key genetic information that will aid them make
the right choices over the right medicine or dosage to use for an effective
treatment, particularly important in time-critical emergency care healthcare
paradigms. Based in the UK, the Company is at the forefront of Point of Care
pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on
how your individual genetics impact a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicine choices can be personalised,
made safer and more effective. The Company has launched its two flagship
products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit,
both developed and validated in collaboration with NHS partners and deployed
on its point of care thermocycler platform. Both tests are single-use
disposable cartridges which are ambient temperature stable, circumventing the
requirement for cold chain logistics. The Directors believe the Genedrive®
MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on
antibiotic use in neonatal intensive care units within 26 minutes, ensuring
vital care is delivered, avoiding adverse effects potentially otherwise
encountered and with no negative impact on the patient care pathway. Its
CYP2C19 ID Kit which has no comparably positioned competitor currently allows
clinicians to make a decision on the use of Clopidogrel in stroke patients in
70 minutes, ensuring that patients who are unlikely to benefit from or suffer
adverse effects from Clopidogrel receive an alternative antiplatelet
therapeutic in a timely manner, ultimately improving outcomes. Both tests have
undergone review by the National Institute for Health and Care Clinical
Excellence ("NICE") and have been recommended for use in the UK NHS. The
Company has a clear commercial strategy focused on accelerating growth through
maximising in-market sales, geographic and portfolio expansion and strategic
M&A, and operates out of its facilities in Manchester.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUBAWRVOURUAA



            Copyright 2019 Regulatory News Service, all rights reserved